Compare IQVIA Holdings Inc. Common Stock (IQV) vs Blue Owl Capital Inc. Class A Common Stock (OWL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IQVIA Holdings Inc. Common Stock vs Blue Owl Capital Inc. Class A Common Stock — how do they compare? IQVIA Holdings Inc. Common Stock trades at $261.7 (market cap $42.91B), while Blue Owl Capital Inc. Class A Common Stock trades at $8.81 (market cap $6.35B). The key difference: IQVIA Holdings Inc. Common Stock is far larger — about 6.8× Blue Owl Capital Inc. Class A Common Stock's market cap, and Blue Owl Capital Inc. Class A Common Stock pays a 9.8% dividend while IQVIA Holdings Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold IQVIA Holdings Inc. Common Stock for 6 Days and Blue Owl Capital Inc. Class A Common Stock for 0 Days on average.
| IQV | OWL | |
|---|---|---|
Market Cap | $42.91B | $6.35B |
Volume | 1,333,456 | 15,716,423 |
Sector | Health | Financials |
52-Week High | $275.02 | $17.17 |
52-Week Low | $156.66 | $8.23 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $57.07B | $10.53B |
Dividend Yield | — | 9.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IQVIA Holdings (IQV) trades at $260.71, down 0.57% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $284.64. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $3.15 surpassing the $3.03 estimate. Revenue growth is steady, projected at $17.0B for 2026, while profitability metrics like a 23.01% ROE and 8.1% net income margin reflect operational strength. The company continues to innovate, launching new predictive analytics tools for life sciences clients.
The outlook for IQV remains positive, supported by strong earnings performance and analyst optimism, though investors should note valuation multiples above sector averages and debt levels. Key risks include competitive pressures in clinical research services and macroeconomic sensitivity affecting client spending.
Blue Owl Capital (OWL) trades at $9.29, down 0.54% on the day, with neutral technical indicators showing support at $9 and resistance at $10. The company reported mixed quarterly earnings, beating expectations in Q4 2025 and Q2 2026 but missing in Q1 2026, with Q3 2026 results pending. Revenue growth remains steady at $2.9B in 2025, projected to $3.0B in 2026, though net margins are thin at 2.71%. Analyst sentiment is positive with 63% buy ratings and a $11.01 consensus target, but private credit fund redemptions and loan quality concerns present headwinds.
OWL offers value at a discount to analyst targets with strong institutional backing, but investors face risks from high P/E valuation (77.42), exposure to private credit volatility, and competitive pressures. The stock's 9.8% dividend yield and embedded fee growth from $31.1B in committed capital support upside, though execution on portfolio quality and redemption management will dictate near-term performance. Neutral outlook with cautious optimism pending Q3 earnings clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IQVIA Holdings Inc. Common Stock
IQVIA provides clinical research, healthcare data, technology, and consulting services to life sciences companies. Its work supports drug development and commercialization.
Read more on IQV →About Blue Owl Capital Inc. Class A Common Stock
Blue Owl Capital Inc. is an alternative asset manager that invests across credit, real assets, and GP strategic capital strategies, providing private capital solutions to businesses and to institutional and individual investors.
Read more on OWL →
